Raphael Fraser, PhD

Assistant Professor

Locations

Biostatistics

Contact Information

Education

PhD, Statistics, Florida State University, Tallahassee, FL, 2015
MS, Statistics, Florida State University, Tallahassee, FL, 2012
MS, Biostatistics, University of the West Indies, Kingston, 2006
BS, Mathematics, University of the West Indies, Kingston, 2001

Biography

Dr. Raphael Fraser works as a statistician for the Bone Marrow Transplant Clinical Trials Network and the Center for International Blood and Marrow Transplant Research. He joined the Division of Biostatistics in the Fall of 2015 and is also an adjunct professor in the Department of Mathematical Sciences at the University of Wisconsin, Milwaukee. Before joining the Division of Biostatistics, Dr. Fraser worked at the Tropical Medicine Research Institute in Kingston, Jamaica where his research focused primarily on sickle cell disease.

Curriculum Vitae

Research Interests

Dr. Fraser's primary focus is on plasma cell disorders which includes diseases such as multiple myeloma and amyloidosis. His research interests are survival analysis, Bayesian statistics, clinical trials, and sample survey methodology.

Oral amoxicillin challenges in low-risk children during a pediatric emergency department visit.

(Vyles D, Chiu A, Routes J, Castells M, Phillips EJ, Visotcky A, Fraser R, Pezzin L, Brousseau DC.) J Allergy Clin Immunol Pract. 2020 Mar;8(3):1126-1128.e1 PMID: 31586667 SCOPUS ID: 2-s2.0-85073824604 10/07/2019
Racial disparities of liver cancer mortality in Wisconsin.

(Bemanian A, Cassidy LD, Fraser R, Laud PW, Saeian K, Beyer KMM.) Cancer Causes Control. 2019 Dec;30(12):1277-1282 PMID: 31531799 PMCID: PMC6858574 SCOPUS ID: 2-s2.0-85073816952 09/19/2019
Reported Knowledge and Management of Potential Penicillin Allergy in Children.

(Vyles D, Mistry RD, Heffner V, Drayna P, Chiu A, Visotcky A, Fraser R, Brousseau DC.) Acad Pediatr. 2019 08;19(6):684-690 PMID: 30703582 SCOPUS ID: 2-s2.0-85063442775 02/01/2019
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades.

(Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P.) Biol Blood Marrow Transplant. 2019 06;25(6):1099-1106 PMID: 30794931 PMCID: PMC6559839 SCOPUS ID: 2-s2.0-85064954131 02/23/2019
Revised International Staging System Is Predictive and Prognostic for Early Relapse (

(Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P.) Biol Blood Marrow Transplant. 2019 04;25(4):683-688 PMID: 30579965 PMCID: PMC6453717 SCOPUS ID: 2-s2.0-85060511135 12/24/2018
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

(Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.) Lancet Haematol. 2019 Mar;6(3):e132-e143 PMID: 30824040 PMCID: PMC6503965 SCOPUS ID: 2-s2.0-85061920512 03/03/2019
Impact of Medical Scribes on Provider Efficiency in the Pediatric Emergency Department.

(Addesso LC, Nimmer M, Visotcky A, Fraser R, Brousseau DC.) Acad Emerg Med. 2019 02;26(2):174-182 PMID: 30069952 SCOPUS ID: 2-s2.0-85055480393 08/03/2018
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

(Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A.) Biol Blood Marrow Transplant. 2018 12;24(12):2443-2449 PMID: 30142419 PMCID: PMC6293469 SCOPUS ID: 2-s2.0-85054709914 08/25/2018
Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study.

(Dhakal B, Kreuziger LB, Rein L, Kleman A, Fraser R, Aster RH, Hari P, Padmanabhan A.) Lancet Haematol. 2018 May;5(5):e220-e231 PMID: 29703336 PMCID: PMC6437775 SCOPUS ID: 2-s2.0-85046022775 04/29/2018
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

(Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A.) Leukemia. 2018 04;32(4):986-995 PMID: 29263438 PMCID: PMC5871538 SCOPUS ID: 2-s2.0-85044662461 12/22/2017
Tandem high-dose chemotherapy and autologous hematopoietic stem cell transplantation (SCT) compared to single SCT for relapsed/refractory germ cell tumors (GCT)

(Kilari, D., Hari, P., Qayed, M., Fraser, R., Davila, O., Kumar, S., Mark, T.M., Nieto, Y. and D'Souza, A..) Journal of Clinical Oncology. 2018 36:6_suppl, 572-572 07/01/2019
Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study

(Hahn, T.E., Wallace, P.K., Fraser, R., Fei, M., Tario, J.D., Howard, A., Zhang, Y., Blackwell, B., Brunstein, C.G., Efebera, Y.A. and Geller, N..) Biology of Blood and Marrow Transplantation , Volume 25 , Issue 3 , S4 - S6. 03/01/2019

Raphael Fraser, PhD